Topical Corticosteroids Market Size 2024-2028

The global topical corticosteroids market is projected to increase by USD 1.36 billion, growing at a CAGR of 4.74% from 2023 to 2028. This growth is driven by advancements in drug delivery systems, particularly for skin disorders, which are on the rise, especially among aging populations. These systems, such as topical gels, creams, lotions, and transdermal patches, offer enhanced bioavailability, reduced side effects, and better patient compliance. The incorporation of nanotechnology and biodegradable polymers has further revolutionized treatments with more targeted and controlled delivery.

For more details about the industry, get the PDF sample report for free

Topical Corticosteroids Market Segmentation

• End-User Outlook:

  • Hospitals
  • Dermatology clinics
  • Pharmacies
  • Others

• Type Outlook:

  • Prescription
  • OTC

• Region Outlook:

  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW (Rest of the World)
    • Australia
    • Argentina
    • Rest of the World

By End User

The hospital segment is poised to experience significant growth during the forecast period, driven by the increasing prevalence of skin disorders such as dermatitis, psoriasis, and eczema. Topical corticosteroids are widely used in hospital dermatology departments for various skin conditions, further supported by growing awareness among healthcare professionals and patients.

Regional Market Trends

• North America:
  • The U.S. and Canada lead the market, primarily due to the growing geriatric population, increasing awareness of skin disorders, and high healthcare infrastructure.
• Asia:
  • Expected to contribute 30% to the global market’s growth, with increasing awareness and treatment demand for skin conditions.
• Europe:
  • Countries such as the U.K., Germany, and France show significant market expansion, supported by a high prevalence of skin diseases.
• ROW (Rest of the World):
  • Australia and Argentina also contribute to the market, though at a smaller scale compared to North America and Asia.

Topical Corticosteroids Market Dynamics

• Drivers:

  • Advancements in drug delivery systems, such as liposomes and nano gels, are improving the efficacy of topical corticosteroids and enhancing patient compliance. This has spurred the market's growth.

• Trends:

  • The growing adoption of generic drugs is a key trend, especially as they provide a more cost-effective alternative to brand-name drugs. Increased competition among drug manufacturers has further reduced prices, making medications more accessible.

• Challenges:

  • The availability of alternative treatments, such as topical calcineurin inhibitors and topical retinoids, presents challenges to market growth. Many patients prefer non-steroidal treatments due to concerns over side effects.

Key Market Driver

Advancements in drug delivery systems are a significant growth driver, improving bioavailability, absorption, and therapeutic efficacy while minimizing systemic exposure. Technologies like microemulsions, solid lipid nanoparticles, and dendrimers are expected to sustain market growth.

Significant Market Trends

The rise of generic drugs, driven by lower costs and patent expirations, is a significant market trend. With increasing competition and market entry by companies like Galderma and AstraZeneca Plc, the accessibility of topical corticosteroids is improving.

Major Market Challenge

The availability of alternative treatments, including topical calcineurin inhibitors, phototherapy, and retinoids, poses a challenge to the growth of the topical corticosteroid market.

Get more details by ordering the complete report

Key Market Players

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bausch Health Co. Inc.
• Bayer AG
• Cipla Ltd.
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• Galderma SA
• GlaxoSmithKline Plc
• Glenmark Pharmaceuticals Ltd.
• LEO Pharma AS
• Merck and Co. Inc.
• Novartis AG
• Perrigo Co. Plc
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Recent Developments

• In January 2024, AbbVie Inc. launched a new topical corticosteroid through its subsidiary Allergan, expanding its portfolio.
• In February 2024, AstraZeneca PLC expanded its operations in North America to support the growing demand for corticosteroid treatments.